Wall Street snapped a two-week losing streak as headlines about President Donald Trump's remarks on tariff policy, economic data on inflation and corporate earnings took center stage. The January U.S.
Sees FY25 free cash flow $6.5B. The company said, “The Company issued its full-year 2025 GAAP diluted EPS guidance range of $4.58 to $4.83 and ...
CVS Health posted Q4 sales of $97.71B, with a 23.3% rise in Health Care Benefits revenue. Fiscal 2025 adjusted EPS guidance ...
Leerink Partnrs upgraded shares of CVS Health (NYSE:CVS – Free Report) from a hold rating to a strong-buy rating in a ...
CVS provided initial 2025 adjusted EPS guidance in the range of $5.75 to $6.00. This reflects expected improvements in Aetna's Medicare Advantage margins and a multi-year $2 billion cost ...
Reports Q4 revenue $97.7B, consensus $96.88B. The company said, “Our integrated model allows us to uniquely deliver a simpler, connected ...
CVS Health Corp issued an optimistic guidance for 2025 stemming from the expected recovery in its insurance business — Aetna's turnaround.
CVS Health (NYSE:CVS – Free Report) had its target price increased by Wolfe Research from 67.00 to 70.00 in a report ...
Pharmacy retailer CVS Health Inc. (NYSE:CVS) is scheduled to report its fourth quarter 2024 earnings on Wednesday,2. Wall ...
U.S. stock futures are little changed as investors watch for January inflation data, and Fed Chair Jerome Powell is set to ...
Shares of CVS Health Corp. continued climbing premarket Thursday after a blockbuster session driven by stronger-than-expected ...